Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1148323

Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study


Barbir, Rinea; Drinković, Nikša; Micek, Vedran; Tűreli, Emre; Gűnday Tűreli, Nazende; Kalčec, Nikolina; Ilić, Krunoslav; Pem, Barbara; Pavičić, Ivan; Turčić, Petra; Vinković Vrček, Ivana
Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study // Nanoinnovation 2021
Rim, Italija, 2021. (poster, međunarodna recenzija, neobjavljeni rad, znanstveni)


CROSBI ID: 1148323 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study
(Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study)

Autori
Barbir, Rinea ; Drinković, Nikša ; Micek, Vedran ; Tűreli, Emre ; Gűnday Tűreli, Nazende ; Kalčec, Nikolina ; Ilić, Krunoslav ; Pem, Barbara ; Pavičić, Ivan ; Turčić, Petra ; Vinković Vrček, Ivana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni

Skup
Nanoinnovation 2021

Mjesto i datum
Rim, Italija, 21. - 24.09.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
nanoformulation, doxorubicine, cardiotoxicity

Sažetak
Doxorubicin (DOX) is an effective chemotherapeutic agent prescribed for treatment of various neoplasms. Its major disadvantage and side effect is irreversible cardiomyopathy. This study aimed to investigate if a novel nanoformulation can reduce DOX cardiotoxicity under in vivo settings. Biomarkers for cardiotoxicity were serum levels of cardiac troponin T (cTnT) and N-terminal prohormone of brain natriuretic peptide (NT- proBNP), routinely used in the diagnosis of myocardial damage and heart failure. Three different DOX formulations were tested: commercially and clinically approved conventional (DOX) and nanoliposomal DOX formulations (nanoDOX) that were compared with novel nanoformulation based on poly(lactic-co-glycolic acid) (PLGA- DOX).Doxorubicin (DOX) is an effective chemotherapeutic agent prescribed for treatment of various neoplasms. Its major disadvantage and side effect is irreversible cardiomyopathy. This study aimed to investigate if a novel nanoformulation can reduce DOX cardiotoxicity under in vivo settings. Biomarkers for cardiotoxicity were serum levels of cardiac troponin T (cTnT) and N- terminal prohormone of brain natriuretic peptide (NT-proBNP), routinely used in the diagnosis of myocardial damage and heart failure. Three different DOX formulations were tested: commercially and clinically approved conventional (DOX) and nanoliposomal DOX formulations (nanoDOX) that were compared with novel nanoformulation based on poly(lactic-co-glycolic acid) (PLGA- DOX).Tested compounds were administrated by intraperitoneal application to male and female Wistar rats four times, once per week. At the end of experiment, cTnT and NT-proBNP were determined in rat serum samples using the enzyme-linked immunosorbent (ELISA) assay. Significant increase in the TnT concentration was observed in animals treated with DOX, while significant decrease in NT-proBNP concentration was noticed in animals treated with nanoDOX. In males treated with DOX, cTnT was significantly upregulated compared to control animals, while nanoDOX and PLGA-DOX showed no significant effect. Concentration of NT-proBNP decreased in male animals treated with all three types of DOX formulations, while the decrease in concentration was observed in female rats treated with nanoDOX formulation. Obtained results indicate beneficial characteristics of novel nanoformulation towards safer clinical use of antitumor agents and highlight the importance of nanotechnology for cancer medicine.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija



POVEZANOST RADA


Projekti:
HRZZ-PZS-2019-02-4323 - Siguran pristup za razvoj nano-sustava za ciljanu isporuku lijekova u mozak (SENDER) (Vinković Vrček, Ivana, HRZZ - 2019-02) ( POIROT)

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Institut za medicinska istraživanja i medicinu rada, Zagreb

Poveznice na cjeloviti tekst rada:

www.nanoinnovation2021.eu

Citiraj ovu publikaciju:

Barbir, Rinea; Drinković, Nikša; Micek, Vedran; Tűreli, Emre; Gűnday Tűreli, Nazende; Kalčec, Nikolina; Ilić, Krunoslav; Pem, Barbara; Pavičić, Ivan; Turčić, Petra; Vinković Vrček, Ivana
Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study // Nanoinnovation 2021
Rim, Italija, 2021. (poster, međunarodna recenzija, neobjavljeni rad, znanstveni)
Barbir, R., Drinković, N., Micek, V., Tűreli, E., Gűnday Tűreli, N., Kalčec, N., Ilić, K., Pem, B., Pavičić, I., Turčić, P. & Vinković Vrček, I. (2021) Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study. U: Nanoinnovation 2021.
@article{article, author = {Barbir, Rinea and Drinkovi\'{c}, Nik\v{s}a and Micek, Vedran and T\H{u}reli, Emre and G\H{u}nday T\H{u}reli, Nazende and Kal\v{c}ec, Nikolina and Ili\'{c}, Krunoslav and Pem, Barbara and Pavi\v{c}i\'{c}, Ivan and Tur\v{c}i\'{c}, Petra and Vinkovi\'{c} Vr\v{c}ek, Ivana}, year = {2021}, keywords = {nanoformulation, doxorubicine, cardiotoxicity}, title = {Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study}, keyword = {nanoformulation, doxorubicine, cardiotoxicity}, publisherplace = {Rim, Italija} }
@article{article, author = {Barbir, Rinea and Drinkovi\'{c}, Nik\v{s}a and Micek, Vedran and T\H{u}reli, Emre and G\H{u}nday T\H{u}reli, Nazende and Kal\v{c}ec, Nikolina and Ili\'{c}, Krunoslav and Pem, Barbara and Pavi\v{c}i\'{c}, Ivan and Tur\v{c}i\'{c}, Petra and Vinkovi\'{c} Vr\v{c}ek, Ivana}, year = {2021}, keywords = {nanoformulation, doxorubicine, cardiotoxicity}, title = {Nanoformulations reduce cardiotoxicity of doxorubicin – in vivo animal study}, keyword = {nanoformulation, doxorubicine, cardiotoxicity}, publisherplace = {Rim, Italija} }




Contrast
Increase Font
Decrease Font
Dyslexic Font